Post by Lonza

Speaking to Pharma's Almanac, Behnam Ahmadian Baghbaderani, VP, Global Head of Commercial and Program Management for Specialized Modalities, shares his perspective on how increasing modality complexity is reshaping CDMO differentiation and specialization strategies. He explains how the rapid rise of complex modalities (such as HPAPIs, ADCs, bispecifics, and cell and gene therapies) is driving a shift toward modality-specific expertise, supported by advanced analytics, robust process development, and tightly controlled GMP execution to address growing technical and regulatory challenges. Read the full article here: https://ow.ly/K7i350Z9Lxi #Lonza #CDMO #Innovation #Specialized Modalities